Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer

Abstract Background As with other alkylating agents, cardiac dysfunction can occur with trabectedin therapy for advanced soft tissue sarcomas (STS) or recurrent ovarian cancer (ROC) where treatment options for advanced disease are still limited. Cardiac safety for trabectedin monotherapy (T) for STS...

Full description

Bibliographic Details
Main Authors: Robin L. Jones, Thomas J. Herzog, Shreyaskumar R. Patel, Margaret von Mehren, Scott M. Schuetze, Brian A. Van Tine, Robert L. Coleman, Roland Knoblauch, Spyros Triantos, Peter Hu, Waleed Shalaby, Tracy McGowan, Bradley J. Monk, George D. Demetri
Format: Article
Language:English
Published: Wiley 2021-06-01
Series:Cancer Medicine
Subjects:
anthracycline
cardiac toxicity
chemotherapy
patient outcomes
soft tissue sarcomas
Online Access:https://doi.org/10.1002/cam4.3903

Internet

https://doi.org/10.1002/cam4.3903

Similar Items